Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Xanthine Oxidase Inhibition in Renal Transplant Recipients (XART)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Roberto S Kalil, University of Iowa Identifier:
First received: April 7, 2011
Last updated: March 24, 2017
Last verified: March 2017
Cardiovascular disease is the leading cause of mortality in kidney transplantation. The enzyme xanthine oxidase may play an important role in the cardiovascular disease of kidney transplant recipients. Inhibiting this enzyme with allopurinol may improve vascular health and protects against cardiovascular complications.

Condition Intervention Phase
Complications of Renal Transplant
Drug: allopurinol or placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Prevention
Official Title: Xanthine Oxidase Inhibition in Renal Transplant Recipients

Resource links provided by NLM:

Further study details as provided by University of Iowa:

Primary Outcome Measures:
  • Cardiovascular events [ Time Frame: 3 years ]
  • Endothelial function [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • Arterial stiffness and markers of inflammation [ Time Frame: 3 years ]

Estimated Enrollment: 120
Study Start Date: February 2011
Estimated Study Completion Date: March 2018
Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Allopurinol Drug: allopurinol or placebo
Daily active drug (allopurinol administered orally) to be compared to daily placebo (sugar pill) administered orally for 3 years.
Placebo Comparator: Placebo (sugar pill) Drug: allopurinol or placebo
Daily active drug (allopurinol administered orally) to be compared to daily placebo (sugar pill) administered orally for 3 years.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 18 years or older
  • both genders
  • recipients of living donor or deceased-donor kidney transplant with stable renal function

Exclusion Criteria:

  • history of gout
  • allergy to allopurinol
  • use of azathioprine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01332799

United States, Iowa
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52240
Sponsors and Collaborators
University of Iowa
Principal Investigator: Roberto S Kalil, MD University of Iowa
  More Information

Responsible Party: Roberto S Kalil, Clinical Associate Professor, University of Iowa Identifier: NCT01332799     History of Changes
Other Study ID Numbers: 201010787
Study First Received: April 7, 2011
Last Updated: March 24, 2017

Keywords provided by University of Iowa:
cardiovascular disease
kidney transplantation

Additional relevant MeSH terms:
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Gout Suppressants
Antirheumatic Agents
Free Radical Scavengers
Protective Agents
Physiological Effects of Drugs processed this record on April 28, 2017